News | PharmaTimes https://pharmatimes.com in-depth news, features and insights for the pharmaceutical and healthcare sectors Fri, 25 Apr 2025 11:27:26 +0000 en-US hourly 1 https://pharmatimes.com/wp-content/uploads/2023/11/PT-icon-150x150.png News | PharmaTimes https://pharmatimes.com 32 32 232894315 Acoramidis approved for heart condition treatment https://pharmatimes.com/news/acoramidis-approved-for-heart-condition-treatment/ Fri, 25 Apr 2025 11:26:43 +0000 https://pharmatimes.com/?p=103154 MHRA authorises drug for adults with rare heart muscle damage

]]> 103154 Genomics study launches to optimise childhood cancer care in Ireland https://pharmatimes.com/news/genomics-study-launches-to-optimise-childhood-cancer-care-in-ireland/ Thu, 24 Apr 2025 11:19:34 +0000 https://pharmatimes.com/?p=103145 It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment

]]> 103145 UCL researchers launch congenital muscular dystrophy research programme https://pharmatimes.com/news/ucl-researchers-launch-congenital-muscular-dystrophy-research-programme/ Wed, 23 Apr 2025 11:16:58 +0000 https://pharmatimes.com/?p=103139 The university has been awarded a £1m grant from LifeArc and Muscular Dystrophy UK

]]> 103139 Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine https://pharmatimes.com/news/novavax-shares-positive-real-world-results-for-jn-1-adapted-covid-19-vaccine/ Tue, 22 Apr 2025 11:21:42 +0000 https://pharmatimes.com/?p=103134 The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine

]]> 103134 FDA approves Click’s digital therapeutic for episodic migraine https://pharmatimes.com/news/fda-approves-clicks-digital-therapeutic-for-episodic-migraine/ Thu, 17 Apr 2025 10:40:03 +0000 https://pharmatimes.com/?p=103132 More than 37 million adults in the US are affected by migraine

]]> 103132 Leqembi approved as first treatment to slow early Alzheimer’s progression https://pharmatimes.com/news/leqembi-approved-as-first-treatment-to-slow-early-alzheimers-progression/ Wed, 16 Apr 2025 09:07:26 +0000 https://pharmatimes.com/?p=103126 European Commission grants authorisation for Eisai and Biogen therapy

]]> 103126 Pepaxti shows effectiveness in heavily pretreated multiple myeloma patients https://pharmatimes.com/news/pepaxti-shows-effectiveness-in-heavily-pretreated-multiple-myeloma-patients/ Wed, 16 Apr 2025 08:54:31 +0000 https://pharmatimes.com/?p=103124 New real-world data reinforce treatment benefit

]]> 103124 New data reinforce daratumumab as standard of care for multiple myeloma https://pharmatimes.com/news/new-data-reinforce-daratumumab-as-standard-of-care-for-multiple-myeloma/ Tue, 15 Apr 2025 07:46:09 +0000 https://pharmatimes.com/?p=103122 Long-term survival projections suggest improved outcomes for patients

]]> 103122 Global data highlights effectiveness of romosozumab https://pharmatimes.com/news/global-data-highlights-effectiveness-of-romosozumab/ Tue, 15 Apr 2025 07:34:34 +0000 https://pharmatimes.com/?p=103120 Studies show improved bone mineral density and healthcare cost reductions

]]> 103120 UK clinical trials regulations signed into law https://pharmatimes.com/news/uk-clinical-trials-regulations-signed-into-law/ Mon, 14 Apr 2025 09:04:53 +0000 https://pharmatimes.com/?p=103118 Major update aims to accelerate research and strengthen patient safety

]]> 103118